BAN2401 (later approved as lecanemab, marketed as Leqembi) was evaluated in a Phase 2B clinical trial for early Alzheimer's disease. This trial used an innovative Bayesian adaptive design and demonstrated dose-dependent amyloid reduction, leading to accelerated approval and subsequent full approval by the FDA["@lowe2018"][@logov2020].
The 201 Study (NCT01767311) was pivotal in establishing the clinical efficacy of anti-amyloid immunotherapy and demonstrated that removing amyloid plaques could translate to meaningful cognitive benefits for patients with early AD.
...
BAN2401 (Lecanemab) Phase 2B Trial
Overview
Mermaid diagram (expand to render)
BAN2401 (later approved as lecanemab, marketed as Leqembi) was evaluated in a Phase 2B clinical trial for early Alzheimer's disease. This trial used an innovative Bayesian adaptive design and demonstrated dose-dependent amyloid reduction, leading to accelerated approval and subsequent full approval by the FDA["@lowe2018"][@logov2020].
The 201 Study (NCT01767311) was pivotal in establishing the clinical efficacy of anti-amyloid immunotherapy and demonstrated that removing amyloid plaques could translate to meaningful cognitive benefits for patients with early AD.
Trial Details
| Parameter | Value | |-----------|-------| | Phase | Phase 2B | | Status | Completed | | NCT ID | NCT01767311 | | Drug | BAN2401 (lecanemab) | | Dosage | 10 mg/kg biweekly (selected dose) | | Patient Population | Early AD (MCI due to AD or mild AD) | | Duration | 18 months | | Enrollment | 856 patients | | Sponsor | Eisai Co., Ltd. |
Mechanism of Action
BAN2401 is a monoclonal antibody that selectively targets and clears soluble amyloid-beta (Aβ) protofibrils, which are believed to be the most toxic form of amyloid in Alzheimer's disease[@sankaranarayanan2020].
Key Mechanisms
Protofibril Binding: High affinity for Aβ protofibrils (soluble oligomeric species)
Plaque Clearance: Effective at removing pre-existing amyloid plaques
Fc Engagement: Triggers immune-mediated clearance through Fc receptor interactions
Peripheral Sink Effect: Promotes redistribution of Aβ from brain to periphery
The antibody specifically targets the 3X42 epitope of Aβ protofibrils, distinguishing it from antibodies that target monomeric Aβ or mature plaques only.
Trial Design
The Phase 2B trial employed an innovative Bayesian adaptive design that represented a significant departure from traditional clinical trial methodology:
Bayesian Adaptive Features
Multiple Dose Arms: Four doses (2.5, 5, 10 mg/kg) plus placebo
Interim Analysis: Bayesian probability assessment at 12 months
Sample Reallocation: Adaptive sample size based on efficacy signals
The relationship between amyloid removal and cognitive outcomes observed in the BAN2401 201 Study provided crucial evidence for the amyloid hypothesis. The dose-dependent correlation between amyloid plaque reduction and slower cognitive decline supported the theory that removing the toxic protein could translate to patient benefits.
Lessons for Future AD Trials
The 201 Study demonstrated several key lessons for Alzheimer's clinical trials:
Early intervention matters: Patients with earlier stage disease showed better responses
Biomarker-driven design: Amyloid PET could serve as a surrogate endpoint
Adaptive designs: Bayesian methods could improve trial efficiency
Appropriate endpoints: Composite cognitive measures like ADCOMS may be more sensitive than single endpoints
Post-Approval Real-World Data
Since FDA approval in 2023, lecanemab (Leqembi) has been administered to thousands of patients. Real-world data has generally confirmed the clinical trial results, though post-marketing surveillance continues to monitor ARIA incidence and long-term outcomes. Additional studies are evaluating the efficacy in diverse populations and long-term safety over multiple years of treatment.